Risk-Adapted Treatment Monitoring in mCRPC APCCC 2022

During the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Anwar Padhani presents risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often).
Original video here: www.urotoday.com/video-lectur...

[@juanca0018]

I belive the term bullshit scans to be a bit much but otherwise I trully liked the rest

[@anwarpadhani]

Agree; I am saying it for effect. I am toning it down especially for mHSPC - where there is level 1 data for its use. My talks reflect this.